Castle Biosciences price to sales ratio CSTL

Market value divided by revenue over the last twelve months, since 2020.

Today, Oct 23, 2026: 2.8×
7-year median: 3.4×
Against its 7-year history: 38th; percentile: 0 is its lowest day, 100 its highest
7-year range: 1.2× to 30.2×
Peer median: 6.9×

Castle Biosciences' price to sales ratio is 2.8× as of Oct 23, 2026.

That is below its 7-year median of 3.4×, close to the middle of its last 7 years.

Over that time it ranged from 1.2× in Aug 2025 to 30.2× in Feb 2021.

The median for 7 diagnostics and research stocks of a similar size is 6.9×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	2.8×	1.7×	3.6×
2025	3.3×	1.2×	3.4×
2024	2.4×	1.9×	3.5×
2023	3.0×	2.0×	6.0×
2022	5.0×	4.3×	13.1×
2021	12.6×	11.9×	30.2×
2020	21.2×	8.0×	22.5×

Against its peers

Companies in Medical - Diagnostics & Research nearest Castle Biosciences' size, closest first, today.

Company	Price to sales ratio
CSTLCastle Biosciences	2.8×
NRCNRC Health	3.5×
CDNACareDx	7.8×
VCYTVeracyte	6.9×
BLLNBillionToOne	12.8×
LNTHLantheus	4.2×
CAICaris Life Sciences	9.1×
BIOBio-Rad Laboratories	3.8×
Peer median	6.9×

Where Castle Biosciences ranks

#23of 61Diagnostics and research stocks with the lowest price to sales ratio

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Castle Biosciences

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.